Eileen van Diest
Endocrinology, Diabetes & Metabolism · Boerne, TXNPI 1356515217
Payments from drug & device makers
Across 176 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$554
- Novo Nordisk$548
- Abbott$413
- Amgen$330
- Boehringer Ingelheim$280
- Tandem Diabetes Care, Inc.$188
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,30497%
- Education$1133%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 39 | $554 |
| Novo Nordisk | 27 | $548 |
| Abbott | 9 | $413 |
| Amgen(2 entities) | 13 | $330 |
| Boehringer Ingelheim | 17 | $280 |
| Tandem Diabetes Care, Inc. | 5 | $188 |
| Sanofi-aventis U.S. LLC | 11 | $180 |
| Ascensia Diabetes Care US Inc. | 7 | $97 |
| AstraZeneca(2 entities) | 6 | $89 |
| Bayer | 4 | $85 |
| Senseonics, Incorporated | 5 | $81 |
| IBSA Pharma Inc. | 4 | $70 |
| Radius Health, Inc. | 4 | $67 |
| Corcept Therapeutics | 3 | $45 |
| Xeris Pharmaceuticals, Inc. | 2 | $43 |
| BETA Bionics, Inc. | 2 | $38 |
| Medtronic | 2 | $32 |
| Axsome Therapeutics, Inc. | 2 | $27 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Novartis | 1 | $24 |
| AbbVie | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| RGH Enterprises LLC | 1 | $21 |
| Globus Medical | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Valeritas, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Alvogen Inc | 1 | $14 |
| Merck | 1 | $13 |
| Vistapharm, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,417 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 267 | $311,419 |
| FarxigaDapagliflozin Propanediol | 21 | $30,188 |
| JardianceEmpagliflozin | 28 | $29,613 |
| TymlosAbaloparatide | 11 | $26,802 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 16 | $23,648 |
| Repatha SureclickEvolocumab | 30 | $22,707 |
| FiaspInsulin Aspart (Niacinamide) | 18 | $18,032 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 14 | $15,645 |
| OzempicSemaglutide | 14 | $14,484 |
| SunosiSolriamfetol Hcl | 15 | $12,769 |
| TirosintLevothyroxine Sodium | 28 | $3,609 |
| Pregabalin ErPregabalin | 13 | $2,929 |
| Levothyroxine Sodium | 79 | $2,929 |
| Liothyronine Sodium | 35 | $1,164 |
| SynthroidLevothyroxine Sodium | 12 | $1,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $554 | $311,419267 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $280 | $45,25742 claims |
| Novo NordiskFiasp, Ozempic | $548 | $32,51632 claims |
| AstraZenecaFarxiga | $89 | $30,18821 claims |
| Radius Health, Inc.Tymlos | $67 | $26,80211 claims |
| Axsome Therapeutics, Inc.Sunosi | $27 | $12,76915 claims |
| IBSA Pharma Inc.Tirosint | $70 | $3,60928 claims |
| AbbVieSynthroid | $23 | $1,11112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Boerne
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.